Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Sol-Gel Technologies Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PATIENT ENROLLMENT FOR OUR ONGOING PHASE-3 CLINICAL TRIAL OF SGT-610 FOR GORLIN SYNDROME HAS BEEN COMPLETED; TOP-LINE RESULTS ARE EXPECTED IN THE FOURTH QUARTER OF 2026 PHASE-1B PROOF-OF-CONCEPT CLINICAL TRIAL OF SGT-210 FOR DARIER DISEASE IS ONGOING SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY AND TWYNEO IN THE U.S. FOR A TOTAL CONSIDERATION OF $16 MILLION TO BE RECEIVED DURING 2025 FOLLOWING RECENT TRANSACTIONS, SOL-GEL'S CASH RUNWAY IS EXPECTED TO EXTEND INTO THE FIRST QUARTER OF 2027 NESS ZIONA, ISRAEL, AUG. 15, 2025 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD.(NASDAQ: SLGL), A DERMATOLOGY COMPANY, PIONEERING TREATMENTS FOR PATIENTS WITH SEVERE SKIN CONDITIONS, CONDUCTING A PHASE-3 CLINICAL TRIAL OF SGT-610 (PATIDEGIB GEL, 2%) FOR GORLIN SYNDROME, AND WITH TWO APPROVED LARGE-CATEGORY DERMATOLOGY PRODUCTS, TWYNEO AND EPSOLAY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDED A CORPORATE UPDATE.

SOL-GEL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

NESS ZIONA, ISRAEL, MAY 23, 2025 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD. (NASDAQ: SLGL), A CLINICAL-STAGE DERMATOLOGY COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDEDMARCH 31, 2025.

SOL-GEL REPORTS FIRST QUARTER 2025 RESULTS

NESS ZIONA, ISRAEL, MAY 01, 2025 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES LTD. (THE COMPANY) (NASDAQ: SLGL), A CLINICAL-STAGE DERMATOLOGY COMPANY, TODAY ANNOUNCED A REVERSE SHARE SPLIT (THE REVERSE SPLIT) OF THE COMPANY'S ISSUED AND OUTSTANDING ORDINARY SHARES, PAR VALUE NIS 0.1 PER SHARE (THE ORDINARY SHARES), AT THE RATIO OF 10-FOR-1, SUCH THAT EACH TEN (10) ORDINARY SHARES SHALL BE CONSOLIDATED INTO ONE (1) ORDINARY SHARE.

SOL-GEL ANNOUNCES REVERSE SHARE SPLIT

SOL-GEL TO RECEIVE $16 MILLION DURING 2025 CASH RUNWAY IS EXPECTED TO EXTEND INTO THE FIRST QUARTER OF 2027; COMPANY EXPECTS TO HAVE SUFFICIENT CASH TO COMPLETE ITS PHASE III CLINICAL TRIAL SGT-610 PHASE III CLINICAL TRIAL TOP-LINE RESULTS ARE EXPECTED IN THE FOURTH QUARTER OF 2026; A SIGNIFICANT MILESTONE IN THE CLINICAL TRIAL OF RECRUITING MORE THAN 80% OF THE PATIENTS HAS BEEN ACHIEVED SOL-GEL NOW ESTIMATES THE U.S. MARKET POTENTIAL FOR SGT-610 TO BE BETWEEN $400 TO $500 MILLION ANNUALLY SGT-210 PHASE 1B TRIAL IN DARIER PATIENTS IS ONGOING; 50% OF THE PATIENTS HAVE ALREADY COMPLETED THE TRIAL NESS ZIONA, ISRAEL, APRIL 17, 2025 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD. (NASDAQ: SLGL), A CLINICAL-STAGE DERMATOLOGY COMPANY, TODAY ANNOUNCED IT HAS ENTERED INTO A PRODUCT PURCHASE AGREEMENT WITH A SUBSIDIARY OF MAYNE PHARMA GROUP LIMITED (ASX: MYX) (MAYNE PHARMA) FOR THE SALE AND EXCLUSIVE LICENSE OF THE U.S. RIGHTS TO EPSOLAY AND TWYNEO.

SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY AND TWYNEO IN THE U.S.

THIS DETAILED MARKET INTELLIGENCE PUBLICATION OFFERS VALUABLE INSIGHTS INTO THE INNOVATIVE TECHNOLOGIES, COMPETITIVE LANDSCAPE, AND EMERGING OPPORTUNITIES THAT ARE RESHAPING THE GLOBAL SURFACE ENGINEERING INDUSTRY THROUGH 2035. THIS DETAILED MARKET INTELLIGENCE PUBLICATION OFFERS VALUABLE INSIGHTS INTO THE INNOVATIVE TECHNOLOGIES, COMPETITIVE LANDSCAPE, AND EMERGING OPPORTUNITIES THAT ARE RESHAPING THE GLOBAL SURFACE ENGINEERING INDUSTRY THROUGH 2035.

GLOBAL SOL-GEL COATINGS MARKET RESEARCH 2025-2035: COMPETITIVE LANDSCAPE, FUNCTIONAL PROPERTIES AND APPLICATIONS, END-USERS, TECHNOLOGY FUNDAMENTALS, OVERVIEW AND GROWTH ANALYSIS

MORI ARKIN'S APPOINTMENT AS INTERIM CEO AS OF JANUARY 1, 2025 APPROVED BY SHAREHOLDERS PHASE 3 CLINICAL TRIAL OF SGT-610 FOR GORLIN SYNDROME IS ONGOING WITH OVER 40 CLINICAL SITES ACTIVATED SGT-210 PROOF-OF-CONCEPT STUDY IN PATIENTS SUFFERING FROM DARIER DISEASE IS ONGOING NESS ZIONA, ISRAEL, NOV. 15, 2024 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD.(NASDAQ: SLGL), A DERMATOLOGY COMPANY, PIONEERING TREATMENTS FOR PATIENTS WITH SEVERE SKIN CONDITIONS, CONDUCTING A PHASE-3 CLINICAL TRIAL OF SGT-610 (PATIDEGIB GEL, 2%) FOR GORLIN SYNDROME, AND WITH TWO APPROVED LARGE-CATEGORY DERMATOLOGY PRODUCTS, TWYNEO AND EPSOLAY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2024, AND PROVIDED A CORPORATE UPDATE.

SOL-GEL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

FOLLOWING RECENT TRANSACTIONS AND COST-CUTTING EFFORTS, SOL-GEL'S CASH RUNWAY IS EXPECTED TO EXTEND INTO THE FIRST QUARTER OF 2026 ONGOING PHASE 3 CLINICAL TRIAL OF SGT-610 FOR GORLIN SYNDROME WITH OVER 30 CLINICAL SITES ACTIVATED; TOP-LINE RESULTS ARE EXPECTED BY THE SECOND QUARTER OF 2026 SGT-210 PROOF-OF-CONCEPT STUDY IN PATIENTS SUFFERING FROM DARIER DISEASE, A SIGNIFICANT UNMET MEDICAL NEED IN DERMATOLOGY, IS ONGOING SOL-GEL SELLS ITS RIGHTS IN THE ABBREVIATED NEW DRUG APPLICATION (ANDA) DRUG PRODUCT GENERIC TO ZORYVE CREAM (ROFLUMILAST CREAM 0.3%) FOLLOWING MANAGEMENT REALIGNMENT, MR. MORI ARKIN, THE COMPANY'S EXECUTIVE CHAIRMAN AND CONTROLLING SHAREHOLDER TO BE APPOINTED AS COMPANY'S INTERIM CEO AS OF JANUARY 1, 2025, SUBJECT TO SHAREHOLDERS APPROVAL SOL-GEL RECENTLY SIGNED LICENSE AGREEMENTS WITH RESPECT TO TWYNEO AND EPSOLAY IN EUROPE AND SOUTH AFRICA AND IS NEGOTIATING ADDITIONAL LICENSE DEALS IN LATIN AMERICA AND OTHER TERRITORIES NESS ZIONA, ISRAEL, AUG. 17, 2024 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD.

UPDATE: SOL-GEL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

FOLLOWING RECENT TRANSACTIONS AND COST-CUTTING EFFORTS, SOL-GEL'S CASH RUNWAY IS EXPECTED TO EXTEND INTO THE FIRST QUARTER OF 2026 ONGOING PHASE 3 CLINICAL TRIAL OF SGT-610 FOR GORLIN SYNDROME WITH OVER 30 CLINICAL SITES ACTIVATED; TOP-LINE RESULTS ARE EXPECTED BY THE SECOND QUARTER OF 2026 SGT-210 PROOF-OF-CONCEPT STUDY IN PATIENTS SUFFERING FROM DARIER DISEASE, A SIGNIFICANT UNMET MEDICAL NEED IN DERMATOLOGY, IS ONGOING SOL-GEL SELLS ITS RIGHTS IN THE ABBREVIATED NEW DRUG APPLICATION (ANDA)DRUG PRODUCT GENERIC TO ZORYVE CREAM(ROFLUMILAST CREAM 0.3%) FOLLOWING MANAGEMENT REALIGNMENT, MR. MORI ARKIN, THE COMPANY'S EXECUTIVE CHAIRMAN AND CONTROLLING SHAREHOLDER TO BE APPOINTED AS COMPANY'S INTERIM CEO AS OF JANUARY 1, 2025, SUBJECT TO SHAREHOLDERS APPROVAL SOL-GEL RECENTLY SIGNED LICENSE AGREEMENTS WITH RESPECT TO TWYNEO AND EPSOLAY IN EUROPE AND SOUTH AFRICA AND IS NEGOTIATING ADDITIONAL LICENSE DEALS IN LATIN AMERICA AND OTHER TERRITORIES NESS ZIONA, ISRAEL, AUG. 16, 2024 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD.

SOL-GEL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

NESS ZIONA, ISRAEL, JULY 15, 2024 (GLOBE NEWSWIRE) -- SOL-GEL TECHNOLOGIES, LTD.(NASDAQ: SLGL), A DERMATOLOGY COMPANY, PIONEERING TREATMENTS FOR PATIENTS WITH SEVERE SKIN CONDITIONS, CONDUCTING A PHASE 3 CLINICAL TRIAL OF SGT-610 (PATIDEGIB GEL, 2%) FOR GORLIN SYNDROME, AND WITH TWO APPROVED LARGE-CATEGORY DERMATOLOGY PRODUCTS, TWYNEOAND EPSOLAY, TODAY ANNOUNCED THAT THE CHIEF EXECUTIVE OFFICER, DR. ALON SERI-LEVY, HAS RECENTLY ADVISED THE SOL-GEL BOARD OF DIRECTORS OF HIS DESIRE TO STEP DOWN FROM HIS POSITION AS CEO AND MEMBER OF THE BOARD.

SOL-GEL TECHNOLOGIES ANNOUNCES MANAGEMENT REALIGNMENT

PHASE 3 CLINICAL TRIAL OF SGT-610 FOR GORLIN SYNDROME WITH THE FIRST PATIENT SCREENED, IS ONGOING. SOL-GEL AND BEIMEI PHARMA ANNOUNCED AN ASSET PURCHASE AGREEMENT TO COMMERCIALIZE TWYNEO IN CHINA, HONG KONG, MACAU, TAIWAN AND ISRAEL, FOR A TOTAL CONSIDERATION OF UP TO $115 MILLION.

Sol-Gel Technologies Ltd.

SLGL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Sol-Gel Technologies Ltd.

SLGL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SLGL